Research To Practice | Oncology Videos

Latest Episodes:

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Urothelial Bladder Cancer Jun 22, 2023

Show notes

Featuring perspectives from Ms Brenda Martone and Dr Jonathan E Rosenberg, including the following topics:

Introduction (0:00)
Overview; Localized Urothelial Bladder Cancer (UBC) (3:56)
First-Line Treatment of Metastatic Disease (34:16)
Sequencing of Therapy for Metastatic UBC (59:44)

NCPD information and select publications

What I Tell My Patients: Faculty Physicians and Nurses Discuss the Role of Antibody-Drug Conjugates in the Management of HER2-Expressing Cancers Across the Oncology Spectrum Jun 21, 2023

Show notes

Featuring perspectives from Dr Lyudmila A Bazhenova, Ms Kelly EH Goodwin, Dr Virginia Kaklamani, Ms Caroline Kuhlman, Ms Alexis N McKinney and Dr Zev Wainberg, including the following topics:

Introduction (0:00)
HER2 as a Therapeutic Target; Antibody-Drug Conjugates (6:15)
HER2-Positive Breast Cancer (23:08)
HER2-Positive Gastrointestinal Cancers (46:14)
HER2-Positive Non-Small Cell Lung Cancer (1:08:14)
Toxicities of Trastuzumab Deruxtecan (1:20:59)

NCPD information and select publications

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung Cancer Jun 20, 2023

Show notes

Featuring perspectives from Dr Edward B Garon, Dr John V Heymach, Dr Corey J Langer, Dr Ticiana Leal, Dr David R Spigel and Dr Helena Yu, including the following topics:

Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC)
- Introduction (0:00)
- Strategies to cope with platinum shortages (3:11)
- Selection of appropriate candidates for neoadjuvant chemoimmunotherapy (5:51)
- Current clinical role of adjuvant anti-PD-1/PD-L1 antibodies (11:03)
- Patient selection for and practical implementation of consolidation durvalumab (15:40)
- Faculty presentation: Dr Heymach (18:05)
Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation
- Adjuvant osimertinib for EGFR mutation-positive localized NSCLC (29:45)
- Potential implications of FLAURA2 (35:43)
- Promising investigational strategies for progressive EGFR-mutant disease (38:15)
- Sequencing of therapies for metastatic NSCLC with EGFR exon 20 insertion mutations (42:01)
- Faculty presentation: Dr Yu (46:07)
Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions
- Selection of first- and later-line treatment for ALK-rearranged NSCLC (54:36)
- Role of RET-targeted therapy in current clinical practice (56:53)
- Selection of therapy for ROS1-positive NSCLC, including for patients with CNS involvement (59:30)
- Faculty presentation: Dr Langer (1:01:25)
Targeting MET, HER2 and KRAS Alterations in NSCLC
- Current clinical role of trastuzumab deruxtecan in NSCLC (1:16:14)
- Therapeutic sequencing for NSCLC with KRAS G12C mutations (1:20:41)
- Management of MET exon 14 mutation-positive NSCLC (1:24:33)
- Faculty presentation: Dr Spigel (1:29:36)
Current Management of Metastatic NSCLC without a Targetable Tumor Mutation
- Anti-PD-1/PD-L1 antibodies for patients for whom biomarker testing is pending (1:38:48)
- Selection of first-line therapy for newly diagnosed metastatic NSCLC without a targetable tumor mutation (1:41:13)
- Role of first-line immunotherapy in PD-L1-negative metastatic NSCLC (1:44:17)
- Implications of antibiotic use and autoimmune toxicity for checkpoint inhibitor efficacy (1:48:15)
- Faculty presentation: Dr Garon (1:53:41)
Future Directions in the Management of Metastatic NSCLC
- Future directions in NSCLC: Tumor treating fields and datopotamab deruxtecan (2:04:14)
- Faculty presentation: Dr Leal (2:13:18)

CME information and select publications

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Diffuse Large B-Cell Lymphoma Jun 19, 2023

Show notes

Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Ms Robin Klebig and Dr Matthew Lunning, including the following topics:

Introduction (0:00)
POLARIX: Polatuzumab Vedotin/R-CHP for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (5:55)
Polatuzumab Vedotin/Bendamustine/Rituximab and Selinexor for Relapsed Disease (24:28)
CD19-Directed Antibody-Drug Conjugate Loncastuximab Tesirine (42:43)
CD19-Directed Monoclonal Antibody Tafasitamab Combined with Lenalidomide (51:16)
CD20 x CD3 Bispecific Antibodies (1:01:02)
CAR (Chimeric Antigen Receptor) T-Cell Therapy (1:19:07)

NCPD information and select publications

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part Series Jun 16, 2023

Show notes

Featuring perspectives from Dr Brian Van Tine, including the following topics:

Introduction (0:00)
Case: A man in his mid 30s with metastatic recurrence of alveolar soft part sarcoma of the shoulder who received ipilimumab/nivolumab; imaging scan suspect for pseudoprogression — Nam Q Bui, MD (11:20)
Case: A woman in her mid 30s with a 3-cm desmoid tumor who refuses treatment and is followed for 4 years, now with spontaneous tumor regression — Atif Hussein, MD, MMM (25:11)
Case: A woman in her late teens with an unresectable, massive 14-cm desmoid tumor who receives sorafenib but has poor tolerance to treatment — Dr Hussein (32:35)
Case: A woman in her early 40s with prior mastectomy for angiosarcoma of the right breast and recurrent disease who receives doxorubicin but develops a bleeding sigmoid mass and widespread metastases — Melanie B Thomas, MD (43:36)
Case: A man in his mid 30s with a 5.5-cm leiomyosarcoma, 1 positive inguinal node and multiregimen-refractory disease — Dr Hussein (53:34)
Case: A woman in her early 50s with past medical history of anemia, renal cell carcinoma and nephrectomy who is diagnosed with Grade I gastrointestinal stromal tumors, spindle cell type; c-KIT mutation — Dr Thomas(59:00)

CME information and select publications

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Acute Myeloid Leukemia, Myelodysplastic Syndromes and Myelofibrosis Jun 15, 2023

Show notes

Featuring perspectives from Ms Ilene Galinsky, Dr Ruben A Mesa, Dr Daniel A Pollyea, Dr Richard M Stone and Dr Sara M Tinsley-Vance, including the following topics:

Introduction (0:00)
Overview of Myeloproliferative Neoplasms and Myelofibrosis (MF) — Impact of Ruxolitinib (5:28)
New Agents in MF — Fedratinib, Momelotinib, Pacritinib (31:13)
Myelodysplastic Syndromes — Management of Low- and High-Risk Disease (52:59)
Overview of Acute Myeloid Leukemia (AML) (1:15:18)
Targeted Therapy for AML (1:26:02)

NCPD information and select publications

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Prostate Cancer Jun 12, 2023

Show notes

Featuring perspectives from Dr Neeraj Agarwal, Ms Kathy D Burns, Ms Susan K Roethke and Dr Sandy Srinivas, including the following topics:

Introduction (0:00)
Overview of Prostate Cancer (5:46)
Intensification of Therapy for Localized Disease (35:19)
Hormone-Sensitive Metastatic Disease (48:04)
PARP Inhibitors (1:02:07)
Radioligand Therapy (1:22:51)

NCPD information and select publications

Meet The Professor: Optimizing the Management of Colorectal Cancer — Part 3 of a 3-Part Series Jun 08, 2023

Show notes

Featuring perspectives from Dr Michael J Overman, including the following topics:

Introduction (0:00)
Case: A woman in her mid 40s with microsatellite instability-high (MSI-H) colorectal adenocarcinoma metastatic to the brain receives pembrolizumab; KRAS G13D and somatic BRCA exon 11 mutations — Warren S Brenner, MD (16:27)
Case: A woman in her late 50s with MSI-H Stage IIIB adenocarcinoma of the colon, BRAF V600E mutation — Eric H Lee, MD, PhD (23:20)
Case: A woman in her early 70s with past medical history of diverticulitis and partial colectomy diagnosed with T1, microsatellite stable (MSS) cecal colon adenocarcinoma, minimum residual disease-negative after resection — Farshid Dayyani, MD, PhD (32:37)
Case: A woman in her late 60s with past medical history of hypothyroidism has mass in right lung consistent with colorectal adenocarcinoma but no evidence of primary or other distant disease — Swati Vishwanathan, MD (42:58)
Case: A woman in her mid 60s with multiregimen-relapsed RAS wild-type, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (46:51)
Case: A man in his mid 60s with MSS metastatic cecal adenocarcinoma and progressive disease on FOLFIRINOX/bevacizumab and capecitabine/bevacizumab maintenance — Dr Brenner (50:13)
Case: A woman in her mid 60s with metastatic BRAF V600E-mutant colorectal adenocarcinoma, with circulating tumor DNA positivity after FOLFOX, heated intraperitoneal chemotherapy and colectomy/debulking surgery — Jeremy Lorber, MD (54:31)

CME information and select publications

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Ovarian Cancer Jun 06, 2023

Show notes

Featuring perspectives from Ms Courtney Arn, Dr David M O'Malley, Dr Richard T Penson and Ms Jaclyn Shaver, including the following topics: